ArticleJournal of cancer research and clinical oncology2025

Cost-effectiveness analysis of pembrolizumab versus chemotherapy in advanced non-small cell lung cancer in China based on real-world studies.

Ning Wan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.